0
0

Accelerated Approval Transparency Act

12/29/2022, 5:48 PM

Congressional Summary of S 4390

Accelerated Approval Transparency Act

This bill requires the Food and Drug Administration to include a summary of the reasons a drug or biologic received accelerated approval to treat a serious or life-threatening disease or condition in the public action package for the drug or biologic.

Current Status of Bill S 4390

Bill S 4390 is currently in the status of Bill Introduced since June 14, 2022. Bill S 4390 was introduced during Congress 117 and was introduced to the Senate on June 14, 2022.  Bill S 4390's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of June 14, 2022

Bipartisan Support of Bill S 4390

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
0
Democrat Cosponsors
0
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 4390

Primary Policy Focus

Health

Alternate Title(s) of Bill S 4390

Accelerated Approval Transparency Act
Accelerated Approval Transparency Act
A bill to require summary approval information with respect to certain approved drugs and biological products.

Comments